The Latest Cardiac and Vascular News
LAGUNA HILLS, Calif., Jan. 4, 2022 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced first-in-human cases of pulsed field cryoablation (PFCA) for the treatment of atrial fibrillation (AF). The cases were performed at Medicover Hospital, Warsaw, Poland by Dr. Pawel Derejko, Head […]
LAGUNA HILLS, Calif., July 6, 2021 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT. The two-hour mapping and ablation procedure was performed by Dr. Tom De Potter, MD, […]
LAGUNA HILLS, Calif., Nov. 12, 2020 /PRNewswire/ — Adagio Medical, Inc., a leading innovator for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), and developer of the intelligent Continuous Lesion Ablation System (iCLAS™), today announced that it has closed a $42.5 million Series E equity financing. Proceeds from the financing will be used to support the ongoing iCLAS™ […]
LAGUNA HILLS, Calif., June 1, 2020 /PRNewswire/ — Adagio Medical, Inc., announces that it has received CE Mark approval for its ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) for the endocardial treatment of paroxysmal (PAF) and persistent (PsAF) atrial fibrillation and atrial flutter. “More than half of all atrial fibrillation (AF) patients are diagnosed with PsAF. There […]
by Tori Leets | Apr 6, 2020 | Ken Dropiewski, Placement Announcement McDermott + Bull has successfully placed Richard Van Bibber as the Vice President of Clinical Affairs at Adagio Medical, Inc. He will be charged with overseeing and managing the company’s sponsored global pre-market and post-market clinical studies and is currently driving the enrollment and […]
LAGUNA HILLS, Calif., Dec. 16, 2019 /PRNewswire/ — Adagio Medical, Inc. (Adagio) today announced it has enrolled the first patient in its iCLAS™ Investigational Device Exemption (IDE) trial. The FDA approved study aims to evaluate the safety and efficacy of Adagio’s ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) in the treatment of persistent atrial fibrillation (PsAF). Data will […]
LAGUNA HILLS, Calif., July 31, 2019 /PRNewswire/ — Adagio Medical, Inc., the developer of iCLAS™, the company’s ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces that the first PsAF patient was successfully treated with its new One Shot+™ cryoablation catheter in a procedure that utilizes only anatomical markers with limited usage […]
LAGUNA HILLS, Calif., Nov. 28, 2018 /PRNewswire/ — Adagio Medical, Inc., developer of the iCLAS™ technology, the company’s ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces updates to its ongoing cryoablation study for Persistent Atrial Fibrillation (PsAF). The study is currently being conducted at two clinical sites […]
LAGUNA HILLS, Calif., Oct. 4, 2018 /PRNewswire/ — Adagio Medical, Inc., the developer of the iCLAS™ technology, the company’s ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces the successful completion of its chronic atrial fibrillation animal study, performed in collaboration with the LIRYC Research Institute of Bordeaux, […]
LAGUNA HILLS, Calif., Oct. 1, 2018 /PRNewswire/ — Adagio Medical, Inc., the developer of the iCLAS™ technology, the company’s ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces that the first patients were successfully treated with its new One Shot+™ cryoablation catheter. The new catheter is aimed at […]
